Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors

Jun 19, 2026BMC cancer

How the body’s internal clock may influence the success of immune checkpoint treatments in solid tumors

AI simplified

Abstract

Early infusion of anti-PD-1 or anti-PD-L1 therapy resulted in a 49% disease control rate compared to 40% for late infusion.

  • Higher disease control rate (DCR) was associated with early infusion compared to late infusion.
  • The difference in DCR remained significant after adjusting for disease stage, age, and ethnicity.
  • The adjusted odds ratio for higher DCR with early infusion was 1.18, suggesting a positive association.
  • Subgroup analyses indicated consistent results across sex, age, stage, and immune checkpoint inhibitor (ICI) agent.
  • Significant results were observed among non-Hispanic patients, while findings for Hispanic patients were inconclusive due to limited sample size.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free